QCM
UTHR icon

Qsemble Capital Management’s United Therapeutics UTHR Stock Holding History

Qsemble Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$364K Sell
671
-380
-36% -$214K 0.05% 315
2026
Q1 		$623K Sell
1,051
-330
-24% -$164K 0.05% 327
2025
Q4 		$673K Buy
+1,381
New +$643K 0.06% 334
2025
Q3 		– Sell
-1,563
Closed -$449K – 612
2025
Q2 		$449K Buy
+1,563
New +$467K 0.04% 332

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Qsemble Capital Management's UTHR Position: Q2 2026 in Review

Qsemble Capital Management reduced its United Therapeutics (UTHR) stake by 36% in Q2 2026, selling an estimated $214K and leaving 671 shares worth $364K. The position accounts for 0.05% of the portfolio, ranked #315.

Qsemble Capital Management first reported a position in UTHR in Q2 2025 and has held it in 4 quarters since. The position peaked at $673K in Q4 2025. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Qsemble Capital Management held 671 shares of United Therapeutics worth $364K as of Q2 2026.
  • Qsemble Capital Management sold 380 United Therapeutics shares in Q2 2026, an estimated $214K.
  • United Therapeutics made up 0.05% of Qsemble Capital Management's portfolio in Q2 2026, its #315 holding.
  • Qsemble Capital Management first reported a position in United Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Qsemble Capital Management's United Therapeutics position peaked at $673K in Q4 2025.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Qsemble Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.